{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:14:14Z","timestamp":1790158454221,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Persistent negative symptoms (PNS), defined as negative symptoms of at least moderate severity that endure over time and are not attributable to other psychopathological dimensions such as depression or parkinsonism, have been associated with poor functional outcomes in schizophrenia, in both chronic stages and in the early phases of the disorder. This post-hoc analysis of a large cohort of schizophrenia spectrum disorder patients within their first 7 years of illness, enrolled in the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST), aimed to: 1) confirm prior findings about the prevalence and clinical impact of unconfounded persistent negative symptoms (PNS) on dropout rates and psychosocial functioning after 12 and 18 months of treatment; and 2) explore the prevalence of enduring negative symptoms (E-NS), defined as persistent negative symptoms either confounded or unconfounded by depression or parkinsonism, and their influence on functional outcome. At week 0, 60.6% of patients exhibited at least one negative symptom of moderate severity. Among them, 42.8% met criteria for unconfounded negative symptoms. After 1 year, the frequency of PNS and E-NS was 7.9% and 15%, respectively, with a prospective consistency around 32%. PNS subjects had similar levels of functioning at week 0 (\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.179,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.194), but worse functioning after 12 (\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.697,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028) and 18 (\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009-0.676,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.024) months of treatment, as compared to those with negative symptoms of similar severity at baseline that did not persist (non-persistent negative symptoms, N-PNS). No difference among groups was observed in drop-out rates. The comparison between the E-NS and N-PNS groups revealed the same functional outcome differences observed in the PNS versus N-PNS comparison. Our findings confirm that long-term persistence of negative symptoms, both primary and secondary, contributes to poor functional outcome. Future research should focus on identifying predictors of symptom persistence to guide the development of targeted interventions aimed at improving long-term functional outcomes in this patient population.\n                  <\/jats:p>","DOI":"10.1038\/s41537-026-00739-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T03:36:12Z","timestamp":1772422572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent negative symptoms in the EULAST cohort: impact on functional outcome"],"prefix":"10.1038","volume":"12","author":[{"given":"Luigi","family":"Giuliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8442-5385","authenticated-orcid":false,"given":"Pasquale","family":"Pezzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia M.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Perrottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-9456","authenticated-orcid":false,"given":"Armida","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-4709","authenticated-orcid":false,"given":"Istvan","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-4754","authenticated-orcid":false,"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-2774","authenticated-orcid":false,"given":"Jurjen J.","family":"Luykx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-3175","authenticated-orcid":false,"given":"Covadonga M.","family":"D\u00edaz-Caneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn H.","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-1719","authenticated-orcid":false,"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-6798","authenticated-orcid":false,"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Winter-van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-7656","authenticated-orcid":false,"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll, C. U. & Schooler, N. R. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr. Dis. Treat. 16, 519\u2013534 (2020).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"739_CR2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.11","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi, S. et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur. Psychiatry 64, e23 (2021).","journal-title":"Eur. Psychiatry"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/14737175.2022.2092402","volume":"22","author":"GM Giordano","year":"2022","unstructured":"Giordano, G. M., Caporusso, E., Pezzella, P. & Galderisi, S. Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert Rev. Neurother. 22, 541\u2013555 (2022).","journal-title":"Expert Rev. Neurother."},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.schres.2015.07.021","volume":"168","author":"SF Austin","year":"2015","unstructured":"Austin, S. F. et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr. Res. 168, 84\u201391 (2015).","journal-title":"Schizophr. Res."},{"key":"739_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-224","volume":"12","author":"CL Hovington","year":"2012","unstructured":"Hovington, C. L., Bodnar, M., Joober, R., Malla, A. K. & Lepage, M. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12, 224 (2012).","journal-title":"BMC Psychiatry"},{"key":"739_CR6","doi-asserted-by":"publisher","unstructured":"Melillo, A. et al. Correlations between negative symptoms and cognitive deficits in individuals at first psychotic episode or at high risk of psychosis: a systematic review. J. Clin. Med. 12, https:\/\/doi.org\/10.3390\/jcm12227095 (2023).","DOI":"10.3390\/jcm12227095"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/wps.21189","volume":"23","author":"P Fusar-Poli","year":"2024","unstructured":"Fusar-Poli, P. et al. The lived experience of mental disorders in adolescents: a bottom-up review co-designed, co-conducted and co-written by experts by experience and academics. World Psychiatry 23, 191\u2013208 (2024).","journal-title":"World Psychiatry"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/wps.21243","volume":"23","author":"C Healy","year":"2024","unstructured":"Healy, C. et al. Sensitivity of the familial high-risk approach for the prediction of future psychosis: a total population study. World Psychiatry 23, 432\u2013437 (2024).","journal-title":"World Psychiatry"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/wps.21240","volume":"23","author":"S Hartmann","year":"2024","unstructured":"Hartmann, S. et al. Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohort. World Psychiatry 23, 400\u2013410 (2024).","journal-title":"World Psychiatry"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/wps.21302","volume":"24","author":"J-P Selten","year":"2025","unstructured":"Selten, J.-P., Schalbroeck, R. & Booij, J. The interaction between social determinants of schizophrenia and brain dopamine circuitry. World Psychiatry 24, 191\u2013192 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR11","first-page":"12","volume":"6","author":"PD Harvey","year":"2009","unstructured":"Harvey, P. D. When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry 6, 12\u201314 (2009).","journal-title":"Psychiatry"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.euroneuro.2020.03.010","volume":"34","author":"P Bucci","year":"2020","unstructured":"Bucci, P. et al. Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning. Eur. Neuropsychopharmacol. 34, 76\u201386 (2020).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","volume":"23","author":"S Galderisi","year":"2013","unstructured":"Galderisi, S. et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur. Neuropsychopharmacol. 23, 196\u2013204 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"739_CR14","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.541","volume":"9","author":"P Rucci","year":"2023","unstructured":"Rucci, P. et al. The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in people with schizophrenia. BJPsych open 9, e168 (2023).","journal-title":"BJPsych open"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/wps.20167","volume":"13","author":"S Galderisi","year":"2014","unstructured":"Galderisi, S. et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 13, 275\u2013287 (2014).","journal-title":"World Psychiatry"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamapsychiatry.2017.4607","volume":"75","author":"S Galderisi","year":"2018","unstructured":"Galderisi, S. et al. Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia: a network analysis. JAMA Psychiatry 75, 396\u2013404 (2018).","journal-title":"JAMA Psychiatry"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamapsychiatry.2020.4614","volume":"78","author":"A Mucci","year":"2021","unstructured":"Mucci, A. et al. Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses. JAMA Psychiatry 78, 550\u2013559 (2021).","journal-title":"JAMA Psychiatry"},{"key":"739_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1333711","volume":"15","author":"GM Giordano","year":"2024","unstructured":"Giordano, G. M. et al. Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia. Front. Psychiatry 15, 1333711 (2024).","journal-title":"Front. Psychiatry"},{"key":"739_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","volume":"29","author":"G Fervaha","year":"2014","unstructured":"Fervaha, G., Foussias, G., Agid, O. & Remington, G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 29, 449\u2013455 (2014).","journal-title":"Eur. Psychiatry"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","volume":"24","author":"G Foussias","year":"2014","unstructured":"Foussias, G., Agid, O., Fervaha, G. & Remington, G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur. Neuropsychopharmacol. 24, 693\u2013709 (2014).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1192\/j.eurpsy.2021.13","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi, S. et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur. Psychiatry 64, e21 (2021).","journal-title":"Eur. Psychiatry"},{"key":"739_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/wps.21317","volume":"24","author":"KE Lewandowski","year":"2025","unstructured":"Lewandowski, K. E. et al. Distinct cognitive trajectories in the early course of psychosis are associated with clinical and functional outcomes longitudinally. World Psychiatry 24, 260\u2013266 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/wps.21315","volume":"24","author":"SS Gangadin","year":"2025","unstructured":"Gangadin, S. S. et al. Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed. World Psychiatry 24, 240\u2013249 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/wps.21265","volume":"24","author":"OD Howes","year":"2025","unstructured":"Howes, O. D., Bukala, B. R., Jauhar, S. & McCutcheon, R. A. The hypothesis of biologically based subtypes of schizophrenia: a 10-year update. World Psychiatry 24, 46\u201347 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/wps.21316","volume":"24","author":"J Tiihonen","year":"2025","unstructured":"Tiihonen, J. et al. Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts. World Psychiatry 24, 250\u2013259 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/wps.21253","volume":"23","author":"S Bhattacharyya","year":"2024","unstructured":"Bhattacharyya, S. et al. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis. World Psychiatry 23, 451\u2013452 (2024).","journal-title":"World Psychiatry"},{"key":"739_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/schbul\/sbj013","volume":"32","author":"JJ Blanchard","year":"2006","unstructured":"Blanchard, J. J. & Cohen, A. S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 32, 238\u2013245 (2006).","journal-title":"Schizophr. Bull."},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","volume":"58","author":"B Kirkpatrick","year":"2001","unstructured":"Kirkpatrick, B., Buchanan, R. W., Ross, D. E. & Carpenter, W. T. Jr A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58, 165\u2013171 (2001).","journal-title":"Arch. Gen. Psychiatry"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eurpsy.2009.03.001","volume":"24","author":"S Galderisi","year":"2009","unstructured":"Galderisi, S. & Maj, M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur. Psychiatry 24, 493\u2013500 (2009).","journal-title":"Eur. Psychiatry"},{"key":"739_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","volume":"186","author":"M Kirschner","year":"2017","unstructured":"Kirschner, M., Aleman, A. & Kaiser, S. Secondary negative symptoms - a review of mechanisms, assessment and treatment. Schizophr. Res. 186, 29\u201338 (2017).","journal-title":"Schizophr. Res."},{"key":"739_CR31","doi-asserted-by":"crossref","unstructured":"Cuijpers, P. et al. Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. World Psychiatry 23, 267\u2013275, (2024).","DOI":"10.1002\/wps.21203"},{"key":"739_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/wps.21304","volume":"24","author":"A O\u2019Neil","year":"2025","unstructured":"O\u2019Neil, A., Rossell, S. L. & Berk, M. Understanding side effects of psychotherapies: implications for clinical practice and research trials. World Psychiatry 24, 194\u2013195 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","volume":"33","author":"RW Buchanan","year":"2006","unstructured":"Buchanan, R. W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 33, 1013\u20131022 (2006).","journal-title":"Schizophr. Bull."},{"key":"739_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/schbul\/sbj056","volume":"32","author":"L Alphs","year":"2006","unstructured":"Alphs, L. An industry perspective on the nimh consensus statement on negative symptoms. Schizophr. Bull. 32, 225\u2013230 (2006).","journal-title":"Schizophr. Bull."},{"key":"739_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr & Marder, S. R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32, 214\u2013219 (2006).","journal-title":"Schizophr. Bull."},{"key":"739_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","volume":"186","author":"A Mucci","year":"2017","unstructured":"Mucci, A., Merlotti, E., \u00dc\u00e7ok, A., Aleman, A. & Galderisi, S. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr. Res. 186, 19\u201328 (2017).","journal-title":"Schizophr. Res."},{"key":"739_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","volume":"5","author":"S Galderisi","year":"2018","unstructured":"Galderisi, S., Mucci, A., Buchanan, R. W. & Arango, C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry 5, 664\u2013677 (2018).","journal-title":"Lancet Psychiatry"},{"key":"739_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cpr.2017.09.007","volume":"58","author":"O Santesteban-Echarri","year":"2017","unstructured":"Santesteban-Echarri, O. et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin. Psychol. Rev. 58, 59\u201375 (2017).","journal-title":"Clin. Psychol. Rev."},{"key":"739_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.schres.2018.07.013","volume":"202","author":"P Watson","year":"2018","unstructured":"Watson, P. et al. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr. Res. 202, 26\u201336 (2018).","journal-title":"Schizophr. Res."},{"key":"739_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1590\/1516-4446-2014-1539","volume":"37","author":"E Leclerc","year":"2015","unstructured":"Leclerc, E., Noto, C., Bressan, R. A. & Brietzke, E. Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Braz. J. Psychiatry 37, 168\u2013176 (2015).","journal-title":"Braz. J. Psychiatry"},{"key":"739_CR41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1176\/ajp.151.10.1417","volume":"151","author":"DI Mayerhoff","year":"1994","unstructured":"Mayerhoff, D. I. et al. The deficit state in first-episode schizophrenia. Am. J. Psychiatry 151, 1417\u20131422 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"739_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0920-9964(99)00043-2","volume":"40","author":"J Edwards","year":"1999","unstructured":"Edwards, J., McGorry, P. D., Waddell, F. M. & Harrigan, S. M. Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr. Res. 40, 147\u2013158 (1999).","journal-title":"Schizophr. Res."},{"key":"739_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.nmd.0000131804.34977.c1","volume":"192","author":"AK Malla","year":"2004","unstructured":"Malla, A. K. et al. Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis?. J. Nerv. Ment. Dis. 192, 455\u2013463 (2004).","journal-title":"J. Nerv. Ment. Dis."},{"key":"739_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4088\/JCP.08m04845yel","volume":"71","author":"M Rapado-Castro","year":"2010","unstructured":"Rapado-Castro, M. et al. Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale. J. Clin. Psychiatry 71, 327\u2013337 (2010).","journal-title":"J. Clin. Psychiatry"},{"key":"739_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.schres.2011.09.006","volume":"133","author":"WC Chang","year":"2011","unstructured":"Chang, W. C. et al. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr. Res. 133, 22\u201328 (2011).","journal-title":"Schizophr. Res."},{"key":"739_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.schres.2014.07.021","volume":"158","author":"A \u00dc\u00e7ok","year":"2014","unstructured":"\u00dc\u00e7ok, A. & Erg\u00fcl, C. Persistent negative symptoms after first episode schizophrenia: a 2-year follow-up study. Schizophr. Res 158, 241\u2013246 (2014).","journal-title":"Schizophr. Res"},{"key":"739_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.schres.2022.09.010","volume":"248","author":"J Unrau","year":"2022","unstructured":"Unrau, J. et al. Subtyping negative symptoms in first-episode psychosis: contrasting persistent negative symptoms with a data-driven approach. Schizophr. Res. 248, 219\u2013227 (2022).","journal-title":"Schizophr. Res."},{"key":"739_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/schbul\/sbab079","volume":"48","author":"D Raucher-Ch\u00e9n\u00e9","year":"2022","unstructured":"Raucher-Ch\u00e9n\u00e9, D. et al. Dynamic interplay between insight and persistent negative symptoms in first episode of psychosis: a longitudinal study. Schizophr. Bull. 48, 211\u2013219 (2022).","journal-title":"Schizophr. Bull."},{"key":"739_CR49","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.4088\/JCP.16m11122","volume":"78","author":"O Puig","year":"2017","unstructured":"Puig, O. et al. Persistent negative symptoms in first-episode psychosis: early cognitive and social functioning correlates and differences between early and adult onset. J. Clin. Psychiatry 78, 1414\u20131422 (2017).","journal-title":"J. Clin. Psychiatry"},{"key":"739_CR50","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/08039488.2021.2015431","volume":"76","author":"L Pelizza","year":"2022","unstructured":"Pelizza, L. et al. Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up. Nord. J. Psychiatry 76, 530\u2013538 (2022).","journal-title":"Nord. J. Psychiatry"},{"key":"739_CR51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/schbul\/sbn094","volume":"36","author":"G Foussias","year":"2010","unstructured":"Foussias, G. & Remington, G. Negative symptoms in schizophrenia: avolition and Occam\u2019s razor. Schizophr. Bull. 36, 359\u2013369 (2010).","journal-title":"Schizophr. Bull."},{"key":"739_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/wps.21338","volume":"24","author":"CU Correll","year":"2025","unstructured":"Correll, C. U. et al. Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adults. World Psychiatry 24, 296\u2013318 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","volume":"10","author":"I Winter-van Rossum","year":"2023","unstructured":"Winter-van Rossum, I. et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry 10, 197\u2013208 (2023).","journal-title":"Lancet Psychiatry"},{"key":"739_CR54","first-page":"22-33;quiz 34","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan, D. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59, 22-33;quiz 34\u201322-33;quiz 57 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"739_CR55","unstructured":"International Conference on Harmonisation. Guideline for Good Clinical Practice E6(R1). Step 4 version, https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf (2016)."},{"key":"739_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"739_CR57","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","volume":"137","author":"RS Wallwork","year":"2012","unstructured":"Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R. & Dickinson, D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 137, 246\u2013250 (2012).","journal-title":"Schizophr. Res."},{"key":"739_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr. & Marder, S. R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32, 214\u2013219 (2006).","journal-title":"Schizophr. Bull."},{"key":"739_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J Gerlach","year":"1993","unstructured":"Gerlach, J. et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 87, 244\u2013252 (1993).","journal-title":"Acta Psychiatr. Scand."},{"key":"739_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","volume":"161","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah, H., Morosini, P. & Gagnon, D. D. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 161, 213\u2013224 (2008).","journal-title":"Psychiatry Res."},{"key":"739_CR61","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.schres.2018.10.019","volume":"206","author":"AR Yung","year":"2019","unstructured":"Yung, A. R., Nelson, B., McGorry, P. D., Wood, S. J. & Lin, A. Persistent negative symptoms in individuals at Ultra High Risk for psychosis. Schizophr. Res. 206, 355\u2013361 (2019).","journal-title":"Schizophr. Res."},{"key":"739_CR62","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00406-024-01808-w","volume":"274","author":"C Ricci","year":"2024","unstructured":"Ricci, C. et al. Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study. Eur. Arch. Psychiatry Clin. Neurosci. 274, 1311\u20131326 (2024).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"739_CR63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jpsychires.2016.06.021","volume":"81","author":"RE Carri\u00f3n","year":"2016","unstructured":"Carri\u00f3n, R. E. et al. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: Associations with risk of conversion to psychosis and functional outcome. J. Psychiatr. Res. 81, 95\u2013101 (2016).","journal-title":"J. Psychiatr. Res."},{"key":"739_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/schbul\/sby115","volume":"45","author":"WC Chang","year":"2019","unstructured":"Chang, W. C. et al. Early-stage negative symptom trajectories and relationships with 13-year outcomes in first-episode nonaffective psychosis. Schizophr. Bull. 45, 610\u2013619 (2019).","journal-title":"Schizophr. Bull."},{"key":"739_CR65","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/wps.21267","volume":"24","author":"C Morgan","year":"2025","unstructured":"Morgan, C., Thara, R., Gureje, O., Hutchinson, G. & Cohen, A. Duration of untreated psychosis: a global perspective. World Psychiatry 24, 49\u201350 (2025).","journal-title":"World Psychiatry"},{"key":"739_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00171-2","volume":"7","author":"M Sabe","year":"2021","unstructured":"Sabe, M., Zhao, N., Crippa, A. & Kaiser, S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. npj Schizophr. 7, 43 (2021).","journal-title":"npj Schizophr."}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00739-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:02:39Z","timestamp":1775739759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-026-00739-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1038\/s41537-026-00739-w","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. received advisory board or consultant fees from the following drug companies outside the submitted work: Angelini, Rovi Pharma, and Boehringer Ingelheim. C.A. has been a consultant to or has received honoraria or grants from Abbot, Acadia, Ambrosetti, Angelini, Biogen, BMS, Boehringer, Carnot, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Rovi, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, Takeda, and Teva. C.A. has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, \u201cA way of making Europe\u201d, financed by the European Union\u2014NextGenerationEU (PMP21\/00051), PI19\/01024. PI22\/01824 CIBERSAM, Madrid Regional Government (B2017\/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundaci\u00f3n Familia Alonso, and Fundaci\u00f3n Alicia Koplowitz. B.E. is part of the Advisory Board of Boehringer Ingelheim, Lundbeck Pharma A\/S, and Orion Pharma A\/S; and has received lecture fees from Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, and Lundbeck Pharma A\/S. I.B. received consulting fees from Gedeon Richter and Johnson & Johnson\/Janssen\/Janssen-Cilag; speaker\u2019s honoraria from Gedeon Richter, Hikma Pharmaceuticals, Johnson & Johnson\/Janssen\/Janssen-Cilag, KRKA, Lundbeck, Medichem Pharmaceuticals Inc. by Unilab and Newron; received research grants from Gedeon Richter; royalties from Oxford University Press. M.D. is the Chief Medical Officer of Minerva Neurosciences. J.T. has participated in research projects funded by grants from Janssen, EU\/Forte, Finnish State Research Funding, and Jane and Aatos Erkko Foundation to his employing institutions; he has served as a consultant to HealthCare Global Village, Janssen, Lundbeck, Orion Pharma, and Teva; given an expert testimony to Janssen; and has received honoraria from Janssen, Lundbeck, Orion Pharma, Otsuka, and Teva; and received support for attending meetings and\/or travel from Teva; all outside the submitted work. S.G. received compensation for serving as a consultant or speaker, or she or the institutions she works for have received research support from the companies or organizations indicated: Angelini, Gedeon Richter-Recordati, Janssen Cilag, Lundbeck Italia, Medscape, Takeda, Rovi Boehringer Ingelheim, and Bristol Myers Squibb. The remaining authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}